Janssen’s Simeprevir May Require Hep C Subpopulation Screening
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.
You may also be interested in...
Janssen Persuades Advisory Committee That Simeprevir Doesn’t Need Contraindication
Janssen presents different analysis than FDA and appears to calm fears of a lack of efficacy in Hep C patients with the Q80K polymorphism.
Is It A Rash Or Photosensitivity? FDA May Have To Distinguish Them In Simeprevir Label
Antiviral Drugs Advisory Committee members debated whether both adverse reactions should be included in the simeprevir label’s “Warnings and Precautions” section and whether photosensitivity should automatically lead to stopping treatment.
FDA AdComm Prep For Gilead’s Sofosbuvir Shows Agency Thinking On HCV Dosing
FDA staff cites a favorable benefit-risk assessment for sofosbuvir, though evidence is insufficient to support dosing recommendation in patients with HCV genotypes 5 and 6. Dosing duration and use in prior nonresponders and pre-transplant patients will be discussed by Antiviral Drugs Advisory Committee Oct. 25.